Proteome Sciences plc announced unaudited sales results for the financial year ended December 31, 2019. Unaudited revenues for the full year increased by 24% to approximately £3.8 million (2018: £3.0 million). TMT® sales and royalties accounted for approximately £2.8 million (2018: £2.2 million), reflecting a greater than 28% year on year growth in that underlying business, driven both by increased sales of TMT® and the launch of TMTpro™ in June 2019.

The company provided earnings guidance for the full year 2019. The company anticipated a significantly reduced loss after tax of approximately £0.5 million (2018: £1.3 million).